Skip to main content
Erschienen in: Pediatric Nephrology 3/2009

01.03.2009 | Original Article

Expression of fibrosis-associated molecules in IgA nephropathy treated with cyclosporine

verfasst von: Beom Jin Lim, Ji Hong Kim, Soon Won Hong, Hyeon Joo Jeong

Erschienen in: Pediatric Nephrology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Cyclosporine (CsA) treatment in immunoglobulin A nephropathy (IgAN) is controversial and has not been widely studied. The aim of this study was to investigate the effects of CsA on renal histology and the expression of interstitial fibrosis-associated molecules in childhood IgAN. The subjects were 18 children (age 4.2–13.9 years; male:female 13:5) who had been treated with CsA for 8 or 12 months and who had renal biopsies before and after treatment. Renal biopsies were assessed by routine histology and immunohistochemistry against osteopontin (OPN), transforming growth factor-β (TGF-β), CD68, and CD34. The degree of proteinuria and mesangial IgA deposits decreased or disappeared after treatment in all cases, and the percentage of patients with diffuse mesangial proliferation decreased from 44.4 to 22.2%. However, interstitial fibrosis developed or was aggravated in nine patients (50%) after treatment and was associated with an increased degree of interstitial inflammation in five patients. Tubular OPN expression (45.3 ± 23.4 vs. 37.6 ± 19.3%) and the degree of CD68-positive macrophage infiltration (136.1 ± 88.2 vs. 132 ± 86.0/mm2) were not increased after CsA treatment, but TGF-β expression was significantly increased (6.4 ± 4.2 vs. 13.3 ± 9.9%; p = 0.025). Microvascular density was increased and peritubular capillaries were of small caliber in inflamed areas. We conclude that increased levels of TGF-β and the development of interstitial fibrosis limit the long-term use of CsA in IgAN patients. Osteopontin and macrophages may be indirectly involved in renal fibrosis by prolonging interstitial inflammation rather than by directly increasing TGF-β expression.
Literatur
1.
Zurück zum Zitat D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, Fellin G, Ragni A, Colasanti G, Minetti L, Ponticelli C (1985) Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine 64:49–60CrossRefPubMed D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, Fellin G, Ragni A, Colasanti G, Minetti L, Ponticelli C (1985) Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine 64:49–60CrossRefPubMed
2.
Zurück zum Zitat Donadio JV Jr (1991) Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin Proc 66:1018–1028CrossRefPubMed Donadio JV Jr (1991) Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin Proc 66:1018–1028CrossRefPubMed
3.
Zurück zum Zitat Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC (2006) Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol 1:1167–1172CrossRefPubMed Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC (2006) Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol 1:1167–1172CrossRefPubMed
4.
Zurück zum Zitat Coppo R, Amore A, Peruzzi L, Mancuso D, Camilla R (2007) Angiotensin antagonists and fish oil for treating IgA nephropathy. Contrib Nephrol 157:27–36PubMed Coppo R, Amore A, Peruzzi L, Mancuso D, Camilla R (2007) Angiotensin antagonists and fish oil for treating IgA nephropathy. Contrib Nephrol 157:27–36PubMed
5.
Zurück zum Zitat Locatelli F, Del Vecchio L, Pozzi C (1999) The patient with IgA glomerulonephritis—what is the role of steroid treatment? Nephrol Dial Transplant 14:1057–1060CrossRefPubMed Locatelli F, Del Vecchio L, Pozzi C (1999) The patient with IgA glomerulonephritis—what is the role of steroid treatment? Nephrol Dial Transplant 14:1057–1060CrossRefPubMed
6.
Zurück zum Zitat Lai KN, Mac-Moune Lai F, Vallance-Owen J (1988) A short-term controlled trial of cyclosporine A in IgA nephropathy. Transplant Proc 20[Suppl 4]:297–303PubMed Lai KN, Mac-Moune Lai F, Vallance-Owen J (1988) A short-term controlled trial of cyclosporine A in IgA nephropathy. Transplant Proc 20[Suppl 4]:297–303PubMed
7.
Zurück zum Zitat Kim PK, Kim KS, Pai KS, Kim JH, Choi IJ (1997) Long-term results of cyclosporine-induced remission of relapsing nephrotic syndrome in children. Yonsei Med J 38:307–318CrossRefPubMed Kim PK, Kim KS, Pai KS, Kim JH, Choi IJ (1997) Long-term results of cyclosporine-induced remission of relapsing nephrotic syndrome in children. Yonsei Med J 38:307–318CrossRefPubMed
8.
Zurück zum Zitat Chábová V, Tesar V, Zabka J, Rychlik I, Merta M, Jirsa M, Stejskalová A (2000) Long term treatment of IgA nephropathy with cyclosporine A. Ren Fail 22:55–62CrossRefPubMed Chábová V, Tesar V, Zabka J, Rychlik I, Merta M, Jirsa M, Stejskalová A (2000) Long term treatment of IgA nephropathy with cyclosporine A. Ren Fail 22:55–62CrossRefPubMed
9.
Zurück zum Zitat Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60:1645–1657CrossRefPubMed Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60:1645–1657CrossRefPubMed
10.
Zurück zum Zitat Young BA, Burdmann EA, Johnson RJ, Alpers CE, Giachelli CM, Eng E, Andoh T, Bennett WM, Couser WG (1995) Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48:439–448CrossRefPubMed Young BA, Burdmann EA, Johnson RJ, Alpers CE, Giachelli CM, Eng E, Andoh T, Bennett WM, Couser WG (1995) Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48:439–448CrossRefPubMed
11.
Zurück zum Zitat Thomas SE, Andoh TF, Pichler RH, Shankland SJ, Couser WG, Bennett WM, Johnson RJ (1998) Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 53:897–908CrossRefPubMed Thomas SE, Andoh TF, Pichler RH, Shankland SJ, Couser WG, Bennett WM, Johnson RJ (1998) Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 53:897–908CrossRefPubMed
12.
Zurück zum Zitat Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland SJ, Alpers CE, Bennett WM, Couser WG, Johnson RJ (1995) Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 6:1186–1196PubMed Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland SJ, Alpers CE, Bennett WM, Couser WG, Johnson RJ (1995) Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 6:1186–1196PubMed
13.
Zurück zum Zitat Lim BJ, Kim PK, Hong SW, Jeong HJ (2004) Osteopontin expression and microvascular injury in cyclosporine nephrotoxicity. Pediatr Nephrol 19:288–294CrossRefPubMed Lim BJ, Kim PK, Hong SW, Jeong HJ (2004) Osteopontin expression and microvascular injury in cyclosporine nephrotoxicity. Pediatr Nephrol 19:288–294CrossRefPubMed
14.
Zurück zum Zitat Hudkins KL, Le QC, Segerer S, Johnson RJ, Davis CL, Giachelli CM, Alpers CE (2001) Osteopontin expression in human cyclosporine toxicity. Kidney Int 60:635–640CrossRefPubMed Hudkins KL, Le QC, Segerer S, Johnson RJ, Davis CL, Giachelli CM, Alpers CE (2001) Osteopontin expression in human cyclosporine toxicity. Kidney Int 60:635–640CrossRefPubMed
15.
Zurück zum Zitat Okada H, Moriwaki K, Konishi K, Kobayashi T, Sugahara S, Nakamoto H, Saruta T, Suzuki H (2000) Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 36:498–506CrossRefPubMed Okada H, Moriwaki K, Konishi K, Kobayashi T, Sugahara S, Nakamoto H, Saruta T, Suzuki H (2000) Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 36:498–506CrossRefPubMed
16.
Zurück zum Zitat Choi IJ, Jeong HJ, Lee HY, Kim PK, Lee JS, Han DS (1990) Significance of mesangial IgA deposition in minimal change nephrotic syndrome: a study of 60 cases. Yonsei Med J 31:258–263CrossRefPubMed Choi IJ, Jeong HJ, Lee HY, Kim PK, Lee JS, Han DS (1990) Significance of mesangial IgA deposition in minimal change nephrotic syndrome: a study of 60 cases. Yonsei Med J 31:258–263CrossRefPubMed
17.
Zurück zum Zitat Habib R, Niaudet P (1994) Comparison between pre- and posttreatment renal biopsies in children receiving cyclosporine for idiopathic nephrosis. Clin Nephrol 42:141–146PubMed Habib R, Niaudet P (1994) Comparison between pre- and posttreatment renal biopsies in children receiving cyclosporine for idiopathic nephrosis. Clin Nephrol 42:141–146PubMed
18.
Zurück zum Zitat Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S (1997) Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 136:531–535CrossRefPubMed Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S (1997) Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 136:531–535CrossRefPubMed
19.
Zurück zum Zitat Scheinman JI, Trachtman H, Lin CY, Langman CB, Chan JC (1997) IgA nephropathy: to treat or not to treat? Nephron 75:251–258CrossRefPubMed Scheinman JI, Trachtman H, Lin CY, Langman CB, Chan JC (1997) IgA nephropathy: to treat or not to treat? Nephron 75:251–258CrossRefPubMed
20.
Zurück zum Zitat Nolin L, Courteau M (1999) Management of IgA nephropathy: evidence-based recommendations. Kidney Int 70:S56–S62CrossRef Nolin L, Courteau M (1999) Management of IgA nephropathy: evidence-based recommendations. Kidney Int 70:S56–S62CrossRef
21.
22.
Zurück zum Zitat Harmankaya O, Ozturk Y, Basturk T, Obek A, Kilicarslan I (2002) Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. Int Urol Nephrol 33:167–171CrossRefPubMed Harmankaya O, Ozturk Y, Basturk T, Obek A, Kilicarslan I (2002) Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. Int Urol Nephrol 33:167–171CrossRefPubMed
23.
Zurück zum Zitat Cattran DC (1991) Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 35:S43–S47PubMed Cattran DC (1991) Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 35:S43–S47PubMed
24.
Zurück zum Zitat Mihatsch MJ, Thiel G, Ryffel B (1988) Histopathology of cyclosporine nephrotoxicity. Transplant Proc 20[Suppl 3]:759–771PubMed Mihatsch MJ, Thiel G, Ryffel B (1988) Histopathology of cyclosporine nephrotoxicity. Transplant Proc 20[Suppl 3]:759–771PubMed
25.
Zurück zum Zitat Franceschini N, Alpers CE, Bennett WM, Andoh TF (1998) Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 32:247–253CrossRefPubMed Franceschini N, Alpers CE, Bennett WM, Andoh TF (1998) Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 32:247–253CrossRefPubMed
26.
Zurück zum Zitat Hamahira K, Iijima K, Tanaka R, Nakamura H, Yoshikawa N (2001) Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome. Pediatr Nephrol 16:723–727CrossRefPubMed Hamahira K, Iijima K, Tanaka R, Nakamura H, Yoshikawa N (2001) Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome. Pediatr Nephrol 16:723–727CrossRefPubMed
27.
Zurück zum Zitat Sarioğlu S, Celik A, Erşen A, Uçer I, Sağlam F, Camsari T, Gülay H (2008) Vascular endothelial growth factor expression and vascularity in renal allograft biopsies. Transplant Proc 40:178–180CrossRefPubMed Sarioğlu S, Celik A, Erşen A, Uçer I, Sağlam F, Camsari T, Gülay H (2008) Vascular endothelial growth factor expression and vascularity in renal allograft biopsies. Transplant Proc 40:178–180CrossRefPubMed
28.
Zurück zum Zitat Atakan A, Arikan H, Macunluoglu B, Tuglular S, Ulfer G, Cakalagaoglu F, Ozener C, Akoglu E (2008) Renal protective effects of leukotriene receptor blockers in an experimental model of cyclosporine nephrotoxicity. Transplant Proc 40:279–284CrossRefPubMed Atakan A, Arikan H, Macunluoglu B, Tuglular S, Ulfer G, Cakalagaoglu F, Ozener C, Akoglu E (2008) Renal protective effects of leukotriene receptor blockers in an experimental model of cyclosporine nephrotoxicity. Transplant Proc 40:279–284CrossRefPubMed
29.
Zurück zum Zitat Namikoshi T, Satoh M, Horike H, Fujimoto S, Arakawa S, Sasaki T, Kashihara N (2006) Implication of peritubular capillary loss and altered expression of vascular endothelial growth factor in IgA nephropathy. Nephron Physiol 102:9–16CrossRef Namikoshi T, Satoh M, Horike H, Fujimoto S, Arakawa S, Sasaki T, Kashihara N (2006) Implication of peritubular capillary loss and altered expression of vascular endothelial growth factor in IgA nephropathy. Nephron Physiol 102:9–16CrossRef
30.
Zurück zum Zitat Heller F, Lindenmeyer MT, Cohen CD, Brandt U, Draganovici D, Fischereder M, Kretzler M, Anders HJ, Sitter T, Mosberger I, Kerjaschki D, Regele H, Schlöndorff D, Segerer S (2007) The contribution of B cells to renal interstitial inflammation. Am J Pathol 170:457–468CrossRefPubMedPubMedCentral Heller F, Lindenmeyer MT, Cohen CD, Brandt U, Draganovici D, Fischereder M, Kretzler M, Anders HJ, Sitter T, Mosberger I, Kerjaschki D, Regele H, Schlöndorff D, Segerer S (2007) The contribution of B cells to renal interstitial inflammation. Am J Pathol 170:457–468CrossRefPubMedPubMedCentral
Metadaten
Titel
Expression of fibrosis-associated molecules in IgA nephropathy treated with cyclosporine
verfasst von
Beom Jin Lim
Ji Hong Kim
Soon Won Hong
Hyeon Joo Jeong
Publikationsdatum
01.03.2009
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 3/2009
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-008-1055-z

Weitere Artikel der Ausgabe 3/2009

Pediatric Nephrology 3/2009 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.